D.E. Shaw & Co
TARO

D.E. Shaw & Co’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

D.E. Shaw & Co’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,345
Closed -$432K – 4847
2023
Q4 		$432K Buy
10,345
+367
+4% +$13.5K ﹤0.01% 3583
2023
Q3 		$376K Sell
9,978
-24,088
-71% -$904K ﹤0.01% 3526
2023
Q2 		$1.29M Sell
34,066
-19,628
-37% -$616K ﹤0.01% 2929
2023
Q1 		$1.31M Sell
53,694
-1,958
-4% -$57.1K ﹤0.01% 2978
2022
Q4 		$1.62M Buy
55,652
+403
+0.7% +$12K ﹤0.01% 3104
2022
Q3 		$1.66M Sell
55,249
-2,583
-4% -$89.1K ﹤0.01% 3167
2022
Q2 		$2.09M Sell
57,832
-1,313
-2% -$50.1K ﹤0.01% 3027
2022
Q1 		$2.56M Buy
59,145
+3,144
+6% +$147K ﹤0.01% 3062
2021
Q4 		$2.81M Sell
56,001
-3,195
-5% -$179K ﹤0.01% 3035
2021
Q3 		$3.77M Sell
59,196
-3,148
-5% -$218K ﹤0.01% 2392
2021
Q2 		$4.49M Sell
62,344
-4,471
-7% -$328K ﹤0.01% 2147
2021
Q1 		$4.93M Sell
66,815
-10,809
-14% -$821K ﹤0.01% 1858
2020
Q4 		$5.7M Sell
77,624
-4,386
-5% -$282K 0.01% 1772
2020
Q3 		$4.5M Sell
82,010
-3,566
-4% -$222K ﹤0.01% 1779
2020
Q2 		$5.69M Sell
85,576
-984
-1% -$66K 0.01% 1573
2020
Q1 		$5.3M Sell
86,560
-5,636
-6% -$418K 0.01% 1426
2019
Q4 		$8.11M Buy
92,196
+25,118
+37% +$2.12M 0.01% 1354
2019
Q3 		$5.06M Buy
67,078
+30,132
+82% +$2.45M 0.01% 1635
2019
Q2 		$3.16M Buy
36,946
+9,624
+35% +$952K ﹤0.01% 1926
2019
Q1 		$2.95M Sell
27,322
-14,523
-35% -$1.45M ﹤0.01% 1895
2018
Q4 		$3.54M Sell
41,845
-18,506
-31% -$1.78M ﹤0.01% 1741
2018
Q3 		$5.93M Buy
60,351
+19,216
+47% +$2.08M 0.01% 1465
2018
Q2 		$4.76M Buy
41,135
+5,543
+16% +$609K 0.01% 1574
2018
Q1 		$3.52M Buy
35,592
+10,494
+42% +$1.06M ﹤0.01% 1652
2017
Q4 		$2.63M Buy
+25,098
New +$2.76M ﹤0.01% 1931
2017
Q2 		– Sell
-1,904
Closed -$222K – 3584
2017
Q1 		$222K Buy
+1,904
New +$211K ﹤0.01% 3081
2016
Q3 		– Sell
-7,900
Closed -$1.15M – 3603
2016
Q2 		$1.15M Sell
7,900
-1,359
-15% -$193K ﹤0.01% 2325
2016
Q1 		$1.33M Buy
9,259
+3,492
+61% +$496K ﹤0.01% 2172
2015
Q4 		$891K Buy
+5,767
New +$842K ﹤0.01% 2719
2014
Q4 		– Sell
-2,774
Closed -$408K – 4306
2014
Q3 		$427K Sell
2,774
-5,364
-66% -$808K ﹤0.01% 3469
2014
Q2 		$1.14M Buy
+8,138
New +$903K ﹤0.01% 2817
2014
Q1 		– Sell
-24,852
Closed -$2.46M – 4707
2013
Q4 		$2.46M Sell
24,852
-17,288
-41% -$1.5M ﹤0.01% 2319
2013
Q3 		$3.2M Sell
42,140
-3,010
-7% -$195K 0.01% 2009
2013
Q2 		$2.52M Buy
+45,150
New +$2.67M ﹤0.01% 1908

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

D.E. Shaw & Co's TARO Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2024, closing a stake of 10,345 shares — an estimated $432K sold.

D.E. Shaw & Co first reported a position in TARO in Q2 2013 and held it in 34 quarters. The position peaked at $8.11M in Q4 2019. 94 funds tracked by Wall St. Rank hold TARO as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,345 Taro Pharmaceutical Industries Ltd. shares in Q1 2024, an estimated $432K.
  • D.E. Shaw & Co first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 34 quarters.
  • D.E. Shaw & Co's Taro Pharmaceutical Industries Ltd. position peaked at $8.11M in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.